Aclaris Therapeutics

Company Deals

Aclaris Therapeutics Licenses JAK Inhibitor ATI-1777 to Pediatrix for Greater China

Fineline Cube Dec 1, 2022

US-based Aclaris Therapeutics Inc. (NASDAQ: ACRS) and Shanghai firm Pediatrix Therapeutics Inc. entered into a...

Company Drug

Hefei Lifeon Gains NMPA Approval for Nexletol Clinical Trials in China

Company Drug

Fujian Cosunter Gains NMPA Clearance for Phase II HBV Study of GST-HG131 and GST-HG141

Company Drug

Anhui Anke’s Allogeneic CAR-T Therapy UTAA09 Approved for r/r B-ALL Trials

Company Drug

Juventas Cell Therapy’s CNCT 19 Gains NMPA Approval for Refractory Lupus Nephritis